Archive | February, 2018

Understanding the Barriers to US Biosimilars

Without a strong biosimilars market, costs for biologics in the US continue trending upward.  The world of drug patents for biosimilars in the United States is far more complex than… The post Understanding the Barriers to US Biosimilars appeared first on DrugPatentWatch. The post Understanding the Barriers to US Biosimilars appeared first on Biotechblog.

Continue Reading

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. This ingredient… The post New tentative approval for Watson Labs drug dienogest; estradiol valerate appeared first on DrugPatentWatch. The post New tentative approval for Watson Labs drug […]

Continue Reading

New patent expiration for Medicis drug SOLODYN

Annual Drug Patent Expirations for SOLODYN Solodyn is a drug marketed by Medicis and is included in one NDA. It is available from three suppliers. There are nine patents protecting… The post New patent expiration for Medicis drug SOLODYN appeared first on DrugPatentWatch. The post New patent expiration for Medicis drug SOLODYN appeared first on […]

Continue Reading

New patent expiration for Sun Pharm drug XIMINO

Annual Drug Patent Expirations for XIMINO Ximino is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Sun Pharm drug XIMINO appeared first on DrugPatentWatch. The post New patent expiration for Sun Pharm drug XIMINO appeared […]

Continue Reading

Which pharmaceutical companies have the most drug patents in Israel?

This chart shows the pharmaceutical companies with the most patents in Israel. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Israel? appeared first on DrugPatentWatch. The post Which pharmaceutical companies have the most drug […]

Continue Reading

One hundred percent fruit juice does not alter blood sugar levels

The results are consistent with prior studies which have shown that consumption of 100% fruit juice is not linked to increasing risk of developing type 2 diabetes. It also supports a growing body of evidence that fruit juice has no significant impact on glycemic control. The study involved comprehensive data analysis that quantitatively evaluated the correlation […]

Continue Reading

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. This ingredient… The post New tentative approval for Watson Labs drug dienogest; estradiol valerate appeared first on DrugPatentWatch. The post New tentative approval for Watson Labs drug […]

Continue Reading

New patent for Astrazeneca Ab drug FARXIGA

Annual Drug Patent Expirations for FARXIGA Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are eighteen patents… The post New patent for Astrazeneca Ab drug FARXIGA appeared first on DrugPatentWatch. The post New patent for Astrazeneca Ab drug FARXIGA appeared first on […]

Continue Reading

Which drugs have the most supplementary protection certificates?

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long… The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch. The post Which drugs have the most supplementary protection certificates? appeared […]

Continue Reading

Researchers test new anti-malaria medication

In continuation of my update on Fosmidomycin Fosmidomycin  Piperaquine An international research team has conducted successful phase II clinical tests of a new anti-malaria medication. The treatment led to a cure in 83 cases. The new combination of drugs was developed by Professor Peter Kremsner of the Tübingen Institute of Tropical Medicine and the company DMG […]

Continue Reading